LONDON – Domain Therapeutics SA sealed a collaboration potentially worth €134 million (US$179.6 million) plus royalties for a discovery-stage program targeting a G protein-coupled receptor (GPCR) implicated in Parkinson's and other neurodegenerative diseases. (BioWorld International)

LONDON – Biotie Therapies Corp. is acquiring Synosia Therapeutics Holding AG in an all-share deal that values the private Swiss company at €93.6 million (US$120.95 million). (BioWorld International)